


Attorney Docket No.: PB60602USW

Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Currently Amended) A compound of formula (I):



(I)

wherein A represents an optionally substituted aryl, or an optionally substituted 5- or 6- membered heterocycl ring, or an optionally substituted bicyclic heterocycl group;

B represents a phenyl or pyridyl ring;

Z represents O, S, SO, or SO₂;

R¹ represents CO₂R⁴, CN, CONR⁵R⁶, CH₂CO₂R⁴, OR⁴, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted SO₂alkyl, SO₂NR⁵R⁶, NR⁵CONR⁵R⁶, COalkyl, 2H-tetrazol-5-yl-methyl, optionally substituted bicyclic heterocycle or optionally substituted heterocycl;

R^{2a} and R^{2b} each independently represents hydrogen, halogen, optionally substituted alkyl, optionally substituted alkoxy, CN, SO₂alkyl, SR⁵, NO₂, optionally substituted aryl, CONR⁵R⁶ or optionally substituted heteroaryl;

R^x represents optionally substituted alkyl wherein 1 or 2 of the non-terminal carbon atoms are optionally replaced by a group independently selected from NR⁴, O and SO_n, wherein n is 0, 1 or 2; or R^x represents optionally substituted CQ^aQ^b-heterocycl, optionally substituted CQ^aQ^b-bicyclic heterocycl or optionally substituted CQ^aQ^b-aryl;

R⁴ represents hydrogen or an optionally substituted alkyl;

R⁵ represents hydrogen or an optionally substituted alkyl;

Attorney Docket No.: **PB60602USW**

R⁶ represents hydrogen or optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted SO₂aryl, optionally substituted SO₂alkyl, optionally substituted SO₂heteroaryl, CN, optionally substituted CQ^aQ^baryl, optionally substituted CQ^aQ^bheteroaryl or COR⁷;

R⁷ represents hydrogen, optionally substituted alkyl, optionally substituted heteroaryl or optionally substituted aryl;

R⁸ represents hydrogen, Cl, CF₃, or C₁₋₃alkyl;

R⁹ represents halogen, hydrogen, CF₃, or C₁₋₃alkyl;

Q^a and Q^b are each independently selected from hydrogen and CH₃, wherein when A is a 6-membered ring the R¹ substituent and pyrrole ring are attached to carbon atoms 1,2-, 1,3- or 1,4- relative to each other, and when A is a five-membered ring or bicyclic heterocyclyl group the R¹ substituent and phenyl ring are attached to substitutable carbon atoms 1,2- or 1,3- relative to each other;

and derivatives thereof.

2. (Original) A compound according to claim 1 wherein A is optionally substituted phenyl, optionally substituted pyridyl or optionally substituted isoquinolinyl.

3. (Canceled).

4. (Currently Amended) A pharmaceutical composition comprising a compound according to ~~any one of~~ claims 1 to 3 or a pharmaceutically acceptable derivative thereof together with a pharmaceutical carrier and/or excipient.

5. (Currently Amended) A compound according to ~~any one of~~ claims 1 to 3 or a pharmaceutically acceptable derivative thereof for use as an active therapeutic substance.

Attorney Docket No.: **PB60602USW**

6. (Currently Amended) A compound according to ~~any one~~ of claims 1 to 3 or a pharmaceutically acceptable derivative thereof for use in the treatment of a condition which is mediated by the action of PGE₂ at EP₁ receptors.
7. (Currently Amended) A method of treating a human or animal subject suffering from a condition which is mediated by the action of PGE₂ at EP₁ receptors which comprises administering to said subject an effective amount of a compound according to ~~any one~~ of claims 1 to 3 or a pharmaceutically acceptable derivative thereof.
8. (Currently Amended) A method of treating a human or animal subject suffering from inflammatory pain, neuropathic pain or visceral pain which method comprises administering to said subject an effective amount of a compound according to ~~any one~~ of claims 1 to 3 or a pharmaceutically acceptable derivative thereof.
9. – 10. (Canceled).